Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 4/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093008 | 0.89 | ALDH1A1 (0.45) | NPBWR1CCR1MCHR1MAPTHTT | |
| SCHEMBL7014533 | 0.89 | ALDH1A1 (0.45) | NPBWR1CCR1MCHR1MAPTHTT | |
| SCHEMBL7094405 | 0.87 | ALDH1A1 (0.34) | NPBWR1CCR1MCHR1MAPTNTRK1 | |
| SCHEMBL7092603 | 0.82 | NPBWR1 (0.38) | NPBWR1CCR1MCHR1MAPTNTRK1 | |
| SCHEMBL7023491 | 0.82 | NPBWR1 (0.38) | NPBWR1CCR1MCHR1MAPTNTRK1 | |
| SCHEMBL7930428 | 0.74 | ALPL (0.35) | CCR1KDM4EALDH1A1LMNANOTUM | |
| SCHEMBL7930426 | 0.74 | ALPL (0.35) | CCR1KDM4EALDH1A1LMNANOTUM | |
| SCHEMBL6177069 | 0.74 | MAPK1 (0.46) | MAPTKDM4EHTTMAPK1ALDH1A1 | |
| SCHEMBL6177066 | 0.74 | MAPK1 (0.46) | MAPTKDM4EHTTMAPK1ALDH1A1 | |
| SCHEMBL7018209 | 0.73 | ALDH1A1 (0.38) | NPBWR1CCR1MCHR1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130123-A1 | 2-Phenyl-2h-pyridazine-3-ones | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-10 | — | — | US | disclosed |
| EP-1272476-A1 | 2-PHENYL-2H-PYRIDAZINE-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001079183-A1 | 2-PHENYL-2H-PYRIDAZINE-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130123-A1 | 2-Phenyl-2h-pyridazine-3-ones | CNPY2, CBR3, CBR1 | NPBWR1 371/4885CCR1 373/4885MCHR1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.